4-(2-Pyridinylthio)pentanoic acid | 1247746-12-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-(2-Pyridinylthio)pentanoic acid
• 英文别名: 4-pyridin-2-ylsulfanylpentanoic acid
• CAS: 1247746-12-8
• 化学式: C₁₀H₁₃NO₂S
• 分子量: 211.28
• InChiKey: AFZIRBOYYNKYFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  75.5
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
  申请人：AbbVie Inc.

  公开号：US20170355769A1

  公开（公告）日：2017-12-14

  The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

  这项发明涉及B7同源物3蛋白（B7-H3）抗体和抗体药物结合物（ADCs），包括使用所述抗体和ADCs的组合物和方法。
• SPECIFIC BINDING PROTEINS AND USES THEREOF
  申请人：Old Lloyd J.

  公开号：US20110076232A1

  公开（公告）日：2011-03-31

  The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.

  本发明涉及特定结合成员，尤其是与扩增的上皮生长因子受体（EGFR）和EGFR的de2-7 EGFR截短形式结合的抗体及其片段。特别是，当发生异常的翻译后修饰时，特定结合成员，尤其是抗体及其片段所识别的表位会被增强或显现。这些特定结合成员在癌症的诊断和治疗中非常有用。本发明的结合成员还可以与化疗药物或抗癌剂以及/或其他抗体或其片段联合使用于治疗中。
• [EN] METHODS FOR PREPARING ANTIBODY DRUG CONJUGATES<br/>[FR] PROCÉDÉS DE PRÉPARATION DE CONJUGUÉS ANTICORPS-MÉDICAMENT
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018065501A1

  公开（公告）日：2018-04-12

  The subject matter described herein is directed to methods of preparing certain antibody-drug conjugates (ADCs) wherein the antibody is linked to the drug through a linker, wherein the drug contains a heteroaryl group having a secondary nitrogen, and the linker is attached to the drug via the secondary nitrogen. The resulting conjugates are useful in treating various diseases and conditions.

  本文描述的主题是关于制备特定抗体药物结合物（ADCs）的方法，其中抗体通过连接剂与药物相连，药物含有具有次级氮的杂芳基团，并且连接剂通过次级氮连接到药物上。所得的结合物在治疗各种疾病和症状方面具有用途。
• [EN] DISCRETE PEG CONSTRUCTS<br/>[FR] CONSTRUCTIONS DE PEG DISCRÈTES
  申请人：EQUIP LLC

  公开号：WO2015023979A1

  公开（公告）日：2015-02-19

  Disclosed are linear discrete PEG constructs, which can be created and produced in a precise and reproducible way. Key to being able to do these things, where x in the discrete PEGX can vary from about 2 to about 64, is that the processes used to make each linear portion is controlled to give essentially one oligomer/one compound. Having a variable length linear discrete PEG construct that is (a) primarily an linear discrete PEG construct with diagnostic or therapeutic groups attached along a chain of attachment cores, which is attached to a preferential locator; (b) is an m-discrete PEG as the terminal construct on the linear portion, and "hidden"; (c) or linear discrete PEG with a terminus group that can be either negatively or positively charged, or neutral; and any of the discrete PEG portions can be designed to be cleaved after entering the cell.

  披露了线性离散PEG构造，可以以精确和可重复的方式创建和生产。能够做到这些的关键是，离散PEGX中的x可以在大约2到大约64之间变化，用于制造每个线性部分的过程被控制，以基本上提供一个寡聚体/一个化合物。具有可变长度的线性离散PEG构造，(a) 主要是具有连接诊断或治疗基团的沿着附着核心链附着的线性离散PEG构造，附着在优选定位器上; (b) 是线性部分上的末端构造的m-离散PEG，并且“隐藏”; (c) 或线性离散PEG，带有可以是负电荷、正电荷或中性的终端基团; 任何离散PEG部分都可以设计为进入细胞后被切割。
• [EN] SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE<br/>[FR] MÉDICAMENTS CONJUGUÉS D'ANTICORPS SILVESTROL ET PROCÉDÉS D'UTILISATION
  申请人：GENENTECH INC

  公开号：WO2017214024A1

  公开（公告）日：2017-12-14

  The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.

  这项发明通常涉及一种与离去基团激活的silvestrol分子。该发明进一步涉及一种抗体药物结合物，包括一个抗体通过连接剂与一个或多个silvestrol药物基团结合，并涉及治疗方法。